Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 12/20 | 0.84 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 2/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | PDE2A | O00408 | 1/20 | 0.61 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.61 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.61 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318138 | 0.95 | PRKDC (0.77) | PRKDCP2RY12PIK3CGATM | |
| SCHEMBL7327041 | 0.90 | PRKDC (0.70) | PRKDCP2RY12 | |
| SCHEMBL7319771 | 0.90 | PRKDC (0.70) | PRKDCP2RY12PIK3CGKDM4EALDH1A1 | |
| SCHEMBL7317064 | 0.89 | PRKDC (0.68) | PRKDCP2RY12PIK3CGKDM4EALDH1A1 | |
| SCHEMBL7328209 | 0.89 | P2RY12 (0.77) | PRKDCP2RY12PIK3CD | |
| SCHEMBL7327201 | 0.88 | PRKDC (0.67) | PRKDCP2RY12 | |
| SCHEMBL30313648 | 0.88 | P2RY12 (0.78) | PRKDCP2RY12PIK3CGPIK3CAPIK3CD | |
| SCHEMBL6362810 | 0.88 | P2RY12 (0.78) | PRKDCP2RY12PIK3CGPIK3CAPIK3CD | |
| SCHEMBL7320699 | 0.88 | PRKDC (0.70) | PRKDCP2RY12 | |
| SCHEMBL7324488 | 0.88 | PRKDC (0.67) | PRKDCP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4646626-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2006500361-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | claimed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | claimed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | claimed |
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | claimed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | claimed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | claimed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1024/4885P2RY12 629/4885PIK3CG 17/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PRKDC 84/4885P2RY12 969/4885PIK3CG 13/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | PRKDC 331/4885P2RY12 4703/4885PIK3CG 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.